Form 4: Alignment Healthcare CEO Sells Shares

Alignment Healthcare CEO John E. Kao reported the sale of company stock valued at over $4.7 million through multiple transactions executed on May 11, 2026.

Summary

• John E. Kao, CEO of Alignment Healthcare, Inc., reported the sale of 280,893 shares of common stock on May 11, 2026, at a weighted-average price of $16.8494 per share.
• An additional 17,107 shares were sold on the same date at a weighted-average price of $17.535 per share.
• These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025.
• Following these sales, Kao beneficially owns 1,784,868 shares of common stock.
• A portion of the reported shares are held indirectly through the JEK Trust, of which Mr. Kao is the trustee.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the CEO selling a significant amount of stock, although the pre-planned nature via a 10b5-1 plan mitigates strong negative sentiment.

Negatives

• CEO John E. Kao sold a significant number of shares, totaling 298,000 shares across two transactions.
• The total value of the reported sales exceeds $4.7 million.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While CEO sales can sometimes signal a lack of confidence, the adoption of a Rule 10b5-1 plan suggests these sales were pre-planned and may not reflect immediate sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may view the CEO's stock sale with caution, potentially impacting short-term share price sentiment.
• The sale, executed under a pre-arranged plan, aims to mitigate concerns about insider trading and may reassure stakeholders about the planned nature of the divestment.

Key Dates

Recommendation

The sale of stock by the CEO, while notable, was conducted under a pre-established Rule 10b5-1 trading plan. This suggests the sale was planned in advance and may not reflect a negative outlook on the company's future performance. Without other significant negative or positive catalysts in this specific filing, a 'hold' recommendation is appropriate, advising investors to monitor further developments and company performance.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Alignment Healthcare, ALHC, John E. Kao, CEO, Rule 10b5-1